Abstract：Objective: To conduct a meta-analysis to determine the diagnostic accuracy of three miRNAs ( miRNA-21,miRNA-155and miRNA-195) in breast cancer (BC),and to evaluate the effectiveness of three miRNAs with common reference-based indirect comparison meta-analysis.Methods: We searched the following databases such as PubMed,EMbase,Medline,The Cochrane Library,Chinese Biological Medicine Database (CBM),China National Knowledge Infrastructure (CNKI),WANFANG Database,Chinese Weipu Database (VIP) from inception to october 2019.The screening,data extraction and quality assessment were conducted in accordance with the inclusion and exclusion criteria by two reviewers independently.Quality assessment was performed using a second version of the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2).Meta-Disc 1.4 and Stata 12.0 software were used to perform Meta analysis.Pooled sensitivity,pooled specificity,pooled positive likelihood ratio,pooled negative likelihood ratio,and pooled diagnostic odds ratio were used to assess the diagnosis efficiency.The summary receiver operating characteristic (SROC) curve was plotted and the area under the ROC curve (AUC) was calculated using RevMan 5.3.Stability was evaluated by sensitivity analysis.Deeks'funnel was used to investigate the publication bias.Relative diagnostic odds ratio (RDOR) was used to perform the indirect comparison meta-analyses of three miRNAs in BC by R software.Results: A total of seventeen documents were included,including a total of 1 576 BC cases,and 987 control cases.A fixed-effect model was used for pooling the studies of miRNA-21 and miRNA-195.The pooled sensitivity,pooled specificity,pooled positive likelihood ratio,pooled negative likelihood ratio,pooled diagnostic odds ratio and the AUC of SROC curve of miRNA in the diagnosis of BC were 0.73 95% confidence interval(CI)(0.69~0.77),0.86(95% CI 0.83~0.89),4.99(95% CI 3.86-6.46),0.34(95% CI 0.29~0.39),15.18(95% CI 10.79~21.37) and 0.885 respectively,and as for miRNA-195 those were 0.76(95% CI 0.72~0.80),0.89(95% CI 0.85-0.93),6.59(95% CI 4.77~9.12),0.27(95% CI 0.23~0.33),28.41(95% CI 17.98~44.89) and 0.910,and as a random effect model was used for miRNA-155 those were 0.81(95% CI 0.78~0.84),0.85(95% CI 0.80-0.89),4.90(95% CI 2.33~10.31),0.16(95% CI 0.07~0.33),44.22(95% CI 11.74~166.53) and 0.933.The results of indirect comparison showed that the diagnostic accuracy has no significant difference among the three miRNAs in diagnosing BC.The Deek's funnel plot asymmetry test showed no significant publication bias.Conclusion: MiRNA-155 was better than miRNA-21 and miRNA-195 in diagnosing BC.
张敏杰, 郭团茂, 杨飞飞. miRNA-21 miRNA-155和miRNA-195诊断乳腺癌间接比较的Meta分析[J]. 河北医学, 2020, 26(11): 1893-1900.
ZHANG Minjie, GUO Tuanmao, YANG Feifei. Diagnostic Accuracy of MiRNA-21 MiRNA-155 and MiRNA-195 for Breast Cancer: A Meta-Analysis and Indirect Comparison. HeBei Med, 2020, 26(11): 1893-1900.
[1] IOrio M V,Ferracin M,Liu C G,et al.MicroRNA gene expression deregulation in human breast cancer[J].Cancer research,2005,65(16):7065~7070. [2] Hannafon B N,Trigoso Y D,Calloway C L,et al.Plasma exosome microRNAs are indicative of breast cancer[J].Breast cancer research:BCR,2016,18(1):90. [3] Asaga S,Kuo C,Nguyen T,et al.Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer[J].Clin Chem,2011,57(1):84~91. [4] 李雪峰,徐建军,张青云.荧光定量PCR检测血清微小RNA-21方法的建立及对乳腺癌诊断的初步应用[J].中华检验医学杂志,2011,34(10):920~925. [5] Wang B,ZhangG Q.The expression and clinical significance of circulating microRNA-21 in serum of five solid tumors[J].Cancer Res Clin Oncol,2012,138(10):1659~1666. [6] Mar-aguilar F,Mendoza-ramirez J A,MALAGON-SANTIAGO I,et al.Serum circulating microRNA profiling for identification of potential breast cancer biomarkers[J].Dis Markers,2013,34(3):163~169. [7] Gao J,Zhang Q,Xu J,et al.Clinical significance of serum miR-21 in breast cancer compared with CA153 and CEA[J].Chin Cancer Res,2013,25(6):743~748. [8] Toraih E A,Mohammed E A,Farrag S,et al.Pilot Study of Serum MicroRNA-21 as a Diagnostic and Prognostic Biomarker in Egyptian Breast Cancer Patients[J].Mol Diagn Ther,2015,19(3):179~190. [9] 石岩,秦岩,宋磊,等.miRNA-21和miRNA-134在乳腺癌患者血清中表达情况及其临床意义[J].中山大学学报(医学科学版),2016,37(6):875~880. [10] 张文昭,李莹,陶才华.血清miR-21、miR-195、miR-222联合检测对早期乳腺癌的诊断价值[J].海南医学院学报,2016,22(14):1591~1593. [11] Han J G,Jiang Y D,Zhang C H,et al.A novel panel of serum miR-21/miR-155/miR-365 as a potential diagnostic biomarker for breast cancer[J].Ann Surg Treat Res,2017,92(2):55~66. [12] Sun Y,Wang M,Lin G,et al.Serum microRNA-155 as a potential biomarker to track disease in breast cancer[J].PLoS One,2012,7(10):e47003. [13] Eichelser C,Flesch-janys D,Chang-claude J,et al.Deregulated serum concentrations of circulating cell-free microRNAs miR-17,miR-34a,miR-155,and miR-373 in human breast cancer development and progression[J].Clin Chem,2013,59(10):1489~1496. [14] Shaker O,Maher M,Nassar Y,et al.Role of microRNAs -29b-2,-155,-197 and -205 as diagnostic biomarkers in serum of breast cancer females[J].Gene,2015,560(1):77~82. [15] 张超,童富云,胡滢.血清microRNA-155水平在乳腺癌早期诊断和预后评价中的作用[J].国际检验医学杂志,2019,40(10):1197~1200. [16] Heneghan H M,Miller N,Lowery A J,et al.Circulating microRNAs as novel minimally invasive biomarkers for breast cancer[J].Ann Surg,2010,251(3):499~505. [17] 朱岩,王恩礼,李晖,等.血清miR-195在乳腺癌诊断中的作用[J].热带医学杂志,2013,13(7):833~836. [18] Zhao F L,Dou Y C,Wang X F,et al.Serum microRNA-195 is down-regulated in breast cancer:a potential marker for the diagnosis of breast cancer[J].Mol Biol Rep,2014,41(9):5913~5922. [19] 许践刚,林峰,张宪波,等.miR-195在乳腺癌患者血浆中的表达及其临床意义[J].温州医科大学学报,2014,44(2):105~108,112. [20] Cho W C.OncomiRs:the discovery and progress of microRNAs in cancers[J].Molecular cancer,2007,6:60. [21] Kim H,Huang W,Jiang X,et al.Integrative genome analysis reveals an oncomir/oncogene cluster regulating glioblastoma survivorship[J].Proceedings of the National Academy of Sciences of the United States of America,2010,107(5):2183~2188. [22] Zhang J G,Wang J J,Zhao F,et al.MicroRNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC)[J].Clinica chimica acta;international journal of clinical chemistry,2010,411(11-12):846~852. [23] Zhu S,Si M L,Wu H,et al.MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1)[J].The Journal of biological chemistry,2007,282(19):14328~14336. [24] Ajuyah P,Hill M,Ahadi A,et al.Hutvagner G,Tran N.MicroRNA (miRNA)-to-miRNA Regulation of Programmed Cell Death 4 (PDCD4).Molecular and cellular biology[J].2019,39(18):e00086~19. [25] 左江成,刘美,耿顺康,等.miR-155在乳腺癌患者组织和血浆中的表达水平及临床意义[J].中国妇幼保健,2019,34(2):439~443. [26] Zhang L,Wang W,Li X,et al.MicroRNA-155 promotes tumor growth of human hepatocellular carcinoma by targeting ARID2[J].International journal of oncology,2016,48(6):2425~2434.
2020, Vol. 26 
冀公网安备13080202000677号